Large neutral amino acid transporter enables brain drug delivery via prodrugs. - Wikidata - awgldk - TriplyDB

Large neutral amino acid transporter enables brain drug delivery via prodrugs.

Large neutral amino acid transporter enables brain drug delivery via prodrugs.

http://www.wikidata.org/entity/Q46793172

about

Rational approaches to improving selectivity in drug design Targeting therapeutics across the blood brain barrier (BBB), prerequisite towards thrombolytic therapy for cerebrovascular disorders-an overview and advancements Preparation of dibenzo[e,g]isoindol-1-ones via Scholl-type oxidative cyclization reactions.Evaluation of active and passive transport processes in corneas extracted from preserved rabbit eyes Overcoming Chemical, Biological, and Computational Challenges in the Development of Inhibitors Targeting Protein-Protein Interactions.Targeting the neurovascular unit for treatment of neurological disorders.Novel central nervous system drug delivery systems.Small endogenous molecules as moiety to improve targeting of CNS drugs.Can formulation and drug delivery reduce attrition during drug discovery and development-review of feasibility, benefits and challenges.Mechanism of brain targeting by dexibuprofen prodrugs modified with ethanolamine-related structures.Immunohistochemical and functional characterization of peptide, organic cation, neutral and basic amino acid, and monocarboxylate drug transporters in human ocular tissues.LAT-1 activity of meta-substituted phenylalanine and tyrosine analogs Prodrug approaches for CNS delivery Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier.Various drug delivery approaches to the central nervous system.Novel and emerging strategies in drug delivery for overcoming the blood-brain barrier.Shuttle-mediated drug delivery to the brain.Medicinal chemistry based approaches and nanotechnology-based systems to improve CNS drug targeting and delivery.CNS drug targeting: have we travelled in right path?Current strategies for targeted delivery of bio-active drug molecules in the treatment of brain tumor.Targeting L-type amino acid transporter 1 for anticancer therapy: clinical impact from diagnostics to therapeutics.Amino Acid Promoieties Alter Valproic Acid Pharmacokinetics and Enable Extended Brain Exposure.Cell-specific, activatable, and theranostic prodrug for dual-targeted cancer imaging and therapy.Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth.Vectorization of agrochemicals: amino acid carriers are more efficient than sugar carriers to translocate phenylpyrrole conjugates in the Ricinus system.Nanocarriers for brain specific delivery of anti-retro viral drugs: challenges and achievements.Molecular and functional characterization of riboflavin specific transport system in rat brain capillary endothelial cells.LAT1 activity of carboxylic acid bioisosteres: Evaluation of hydroxamic acids as substrates Amino Acid Carbamates As Prodrugs Of Resveratrol.Direct access to benzo[b]furans through palladium-catalyzed oxidative annulation of phenols and unactivated internal alkynes.Design, synthesis and brain uptake of LAT1-targeted amino acid prodrugs of dopamine.Targeting glioma stem cells through combined BMI1 and EZH2 inhibition.Rational design and structure-activity relationship studies of quercetin-amino acid hybrids targeting the anti-apoptotic protein Bcl-xL.LAT1-mediated prodrug uptake: a way to breach the blood-brain barrier?Mustard-inspired delivery shuttle for enhanced blood-brain barrier penetration and effective drug delivery in glioma therapy.Blood-brain barrier permeability and brain uptake mechanism of kainic acid and dihydrokainic acid.Quantitative insight into the design of compounds recognized by the L-type amino acid transporter 1 (LAT1).Functional Polarity of Microvascular Brain Endothelial Cells Supported by Neurovascular Unit Computational Model of Large Neutral Amino Acid Homeostasis.Insights into the Structure, Function, and Ligand Discovery of the Large Neutral Amino Acid Transporter 1, LAT1.The Human SLC7A5 (LAT1): The Intriguing Histidine/Large Neutral Amino Acid Transporter and Its Relevance to Human Health.

P2860

Q26865357-61D7BAF1-EAD1-4668-A12D-43F537D5E0A8 Q30393215-80763CAB-97A9-451B-B3AD-6E0931417F47 Q34141705-A8527D24-966D-4ECE-81B7-FB03830E0B7A Q34141933-BF33A082-E97B-4611-B375-304DC2584B70 Q34481459-64EA3469-1708-4A5B-A326-D2C7B4A0A022 Q34974827-79DD256D-BC91-4C1A-B3BF-D2D155C38FCF Q35064473-6944BDB6-6FE5-4340-BCB5-A3D26F8DEDF6 Q36065879-F0A9504A-494B-4A42-9B3A-CC369CFDE75C Q36111924-EAF8A8AD-64C6-4068-B08A-2AF1DD89C451 Q36350484-58DFD321-EC99-4783-917E-C6951C3ADDA5 Q36573373-55987A0D-A293-4692-A116-A16827E8370E Q36923089-A1AF1D25-8D88-4A90-98A1-D7AD500EF4D8 Q37150860-78616723-20E9-4611-B202-30867B5E9C78 Q37312010-9C598AD2-3855-40CD-B27D-EE0A4933FAAE Q37657525-333281EB-801A-43C2-8E4E-E3E861DFF4A9 Q37855817-87D57255-4227-40D8-876C-B456E3B0CE7A Q37896550-792628A8-2320-43C3-BE23-BDF7823C796E Q37995554-8AB4BDEE-A320-4CCE-BAA9-8364DBE4DC4B Q38127262-773E9D40-A5D4-4A2B-BCA2-5CCA9226694B Q38401892-913D4FF3-AE30-4A88-B3B0-66878564AA9F Q38476583-FD8566E7-5985-4C95-B324-C96F40C73DA6 Q38758331-66D6F832-4C5A-4BCB-BE14-5F5469A6B519 Q38785651-E608FF6C-0280-407C-84C6-53F964E5110A Q38944343-D432F235-3E54-4439-B1D7-E18E51F2D377 Q39103084-734A7E54-A2EC-4E74-8794-0E8811E1B040 Q40060003-6E636202-DAC1-44B6-8226-E676069179E4 Q41833147-178BF642-782A-4E9B-9FD5-1F51C47D11DA Q42221833-46497F27-A706-4C20-8E00-12484BB114D5 Q42592297-55B80115-F7F1-442D-A314-1E97486D9D65 Q43932409-95D82A7C-FEBC-4978-AE7E-B92B5D1FF90C Q45951082-2C00C9D8-3FAE-461F-BF68-4E040CC7F584 Q47648829-0C081452-81A5-4C9A-8DE8-523EB1DFE3C4 Q47810232-529E98BE-67A5-48C2-9DCE-35A0B40B1076 Q48148305-EA67AB19-6016-4EF9-9090-02C21F24FC2F Q48229575-C95A2036-0492-4482-9120-2310BAE181F4 Q48419626-56A50480-E97A-4B20-BF5C-29490FE90E17 Q48554104-759DF93A-99E9-46D9-B061-B48CD613A277 Q52338806-55889102-6295-4A29-B9D8-359FE27549FD Q52563214-5D4DE9F3-C921-4702-B3DD-45AEACA2631E Q55514831-77BB4903-AA6B-4516-B7BF-E8D5BB2B79B1

P2860

Large neutral amino acid transporter enables brain drug delivery via prodrugs.

http://www.wikidata.org/entity/Q46793172

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Large neutral amino acid transporter enables brain drug delivery via prodrugs.

@en

Large neutral amino acid transporter enables brain drug delivery via prodrugs.

@nl

type

label

Large neutral amino acid transporter enables brain drug delivery via prodrugs.

@en

Large neutral amino acid transporter enables brain drug delivery via prodrugs.

@nl

prefLabel

Large neutral amino acid transporter enables brain drug delivery via prodrugs.

@en

Large neutral amino acid transporter enables brain drug delivery via prodrugs.

@nl

P1433

Q46793172-5DE4C026-4EE2-4BCE-B838-332A9077015D

P1476

Q46793172-4C8F6156-4816-4919-8365-C23395E01DD3

P2093

Q46793172-04FD6F2E-D4D9-487A-BC01-34AF5D81A618

Q46793172-0FBFE16A-FA10-4644-8757-F083DE0F97EF

Q46793172-246CC60D-A7E6-4A79-BA0D-936457FB6820

Q46793172-B7BFA1BB-F555-4541-97AB-7B30D323C5BA

Q46793172-C42901DA-0FE7-4730-938B-E784D960D742

Q46793172-C77C6578-F84F-477A-871F-0511871AB2D2

Q46793172-D9A505FA-4A56-4BAA-A847-BE9C835CFDEF

Q46793172-E6CDCA91-9CED-4BE1-85ED-039E465E6885

P304

Q46793172-D615E26E-85D2-4FB1-AACE-5743B1085A8C

P31

Q46793172-1703DFEA-30BF-4307-AABC-75CDD010D7FC

P356

Q46793172-99EF7002-1F9D-44E9-A866-8A0B6DEB74D2

P407

Q46793172-93855CE0-C53E-45DD-9B61-C0FC3D5C2156

P433

Q46793172-403A7EC3-149F-46A6-9A96-05D3296C23A4

P478

Q46793172-C8A81AB9-B7C3-47FB-BB89-3203383ABB45

P50

Q46793172-0383584D-7157-4329-A4FE-2B85AC8AB534

P577

Q46793172-9807FB7C-A2A4-4792-8644-F6F67ADF6AA0

P698

Q46793172-B320C9F2-D765-4631-BDA0-FA6FCC20179C

P921

Q46793172-5526A8F7-5213-4B8A-8849-9C6307225FEF

P356

P1433

Journal of Medicinal Chemistry

P1476

Large neutral amino acid transporter enables brain drug delivery via prodrugs.

@en

P2093

Anne Mannila

http://www.w3.org/2001/XMLSchema#string

Jarmo Ropponen

http://www.w3.org/2001/XMLSchema#string

Jouko Savolainen

http://www.w3.org/2001/XMLSchema#string

Jukka Leppänen

http://www.w3.org/2001/XMLSchema#string

Krista Laine

http://www.w3.org/2001/XMLSchema#string

Mikko Gynther

http://www.w3.org/2001/XMLSchema#string

Tapio Nevalainen

http://www.w3.org/2001/XMLSchema#string

Tomi Järvinen

http://www.w3.org/2001/XMLSchema#string

P304

932-936

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/JM701175D

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-01-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18217702

http://www.w3.org/2001/XMLSchema#string

P921